Kenvue Inc. (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson, navigates a challenging operating environment. The company faces headwinds from destocking, low disease incidence, and slowing retail trends.
Top-line performance has been weaker than expected through 2025. Analysts point to destocking pressures and low illness rates reducing demand. Kenvue's 2025 guidance projects low single-digit revenue decline and 8.5-12.5% EPS drop.
Skin Health and Beauty segments are bright spots, showing signs of improvement. These segments offer better margins and growth potential. The company's gross profit margin stands at 58.6%.
Kenvue is searching for a permanent CEO and conducting a strategic review. These initiatives will shape the company's future direction, analysts say. The outcome of the strategic review is closely watched by investors.
The company also faces litigation risks. These could impact financial results. The stock trades at a P/E of 20.9 and PEG of 0.39, with a dividend yield of 4.73%. Analysts project EPS of $1.03, $1.08, and $1.23 for upcoming years.
Barclays Capital Inc. rates Equal Weight with an $18 target. Jefferies rates Buy with a $23 target. This analysis is based on reports from October 27 to November 10, 2025.
